SCHEMBL6819989

SCHEMBL6819989

N#Cc1ccc(NC(=O)c2cccc(S(=O)(=O)Cl)c2)c(C(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALB P02768 5/20 0.54
SIRT2 Q8IXJ6 1/20 0.51
AKR1C4 P17516 2/20 0.49
AKR1C3 P42330 2/20 0.49
AKR1C2 P52895 2/20 0.49
AKR1C1 Q04828 2/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
GFER P55789 1/20 0.49
APEX1 P27695 1/20 0.47
TP53 P04637 1/20 0.47
KAT6A Q92794 2/20 0.47
SERPINE1 P05121 1/20 0.47
PKM P14618 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PPARG P37231 2/20 0.46
PPARD Q03181 2/20 0.46
PPARA Q07869 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6352313 0.88 SIRT2 (0.51) ALBSIRT2MEN1KMT2AKAT6A
SCHEMBL6357017 0.83 MEN1 (0.64) AKR1C4AKR1C3AKR1C2AKR1C1MEN1
SCHEMBL6351469 0.83 AKR1C2 (0.66) ALBAKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL6349631 0.83 ALB (0.52) ALBSIRT2MEN1KMT2AGFER
SCHEMBL6359330 0.83 TP53 (0.72) ALBMEN1KMT2ATP53SMN1; SMN2
SCHEMBL6354039 0.83 TP53 (0.69) ALBTP53SMN1; SMN2PPARGPPARD
SCHEMBL6353963 0.83 KMT2A (0.62) ALBAKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL6358764 0.82 TP53 (0.71) ALBMEN1KMT2ATP53SMN1; SMN2
SCHEMBL6350731 0.82 TP53 (0.71) ALBMEN1KMT2ATP53SMN1; SMN2
SCHEMBL6920399 0.81 LMNA (0.52) ALBMEN1KMT2ATP53KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004018414-A2 ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO disclosed